(TheNewswire)
Calgary, Alberta – TheNewswire – February 26, 2026 -Ocumetics Technology Corp. (“Ocumetics” or the “Company”)
OTC (OTCQB: OTCFF) (FRA: 2QBO), a frontrunner in subsequent era
ophthalmic know-how, at this time announcedthe formation of a Scientific Advisory Committee(SAC) to assist the Company’s advancing medical, regulatory, andcommercialization technique because it progresses towards late-stagedevelopment.
The SAC will present impartial, multidisciplinaryexpertise throughout medical trial design, regulatory technique, surgicalapplication, lens science, and translational analysis, guaranteeing strongclinical governance and knowledgeable determination making as Ocumetics preparesfor pivotal medical research and future FDA engagement. The SAC willinclude Dr Ron Krueger, MD, MSE, a globally recognizedophthalmologist, surgeon, and innovator in refractive and cataractsurgery.
Dr. Krueger brings a long time of management in clinicalresearch, surgical innovation, and know-how translation, includingextensive expertise guiding ophthalmic gadgets via advancedclinical growth. Dr. Krueger is the McGraw Professor andChairman of Ophthalmology on the University of Nebraska MedicalCenter. He was beforehand on workers at Cleveland Clinic LernerCollege of Medicine of Case Western Reserve University and a seniorstaff surgeon on the Cleveland Clinic Cole Eye Institute. He isinternationally acknowledged for his pioneering contributions to laservision correction, cataract surgical procedure, and presbyopia remedy, and hasauthored greater than 300 peer-reviewed publications, e-book chapters, andscientific shows. Dr. Krueger has served as a principalinvestigator in quite a few medical trials and has suggested multipleophthalmic machine corporations on medical growth, regulatorystrategy, and surgical adoption.
“Dr. Krueger’s scientific rigor, clinical insight,and experience translating innovation into clinical practice make himan ideal addition to our Scientific Advisory Committee,” mentioned DeanBurns, President and CEO of Ocumetics. “As we enter a more complexphase of development, this committee structure ensures we are drawingfrom the best collective expertise to guide our clinical execution andregulatory strategy.”
The Scientific Advisory Committee will operate as astrategic advisory physique, offering steerage on:
-
Clinical trial design and endpointoptimization
-
First-in-human and pivotal research execution
-
Regulatory technique and FDA engagement
-
Surgical usability and adoption issues
-
Risk evaluation and medical governance
-
Commercialization readiness and physicianeducation
Additional members of the SAC will likely be introduced in thecoming months. Ocumetics stays targeted on advancing itsaccommodating intraocular lens know-how via medical validationand regulatory milestones, with the objective of delivering innovativevision options to sufferers worldwide.
About Ocumetics
Ocumetics Technology Corp. (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO)is a Canadian analysis and product growth firm that isdedicated to creating superior imaginative and prescient correction options thatenhance the standard of life for sufferers. Through innovativeresearch and growth, Ocumetics goals to rework the sector ofophthalmology with state-of-the-art intraocular lenses and othervision-enhancing applied sciences.
Ocumetics is within the first-in-human early feasibilitystudy part of a game-changing know-how for the ophthalmic business. Ocumetics has developed an intraocular lens that matches inside thenatural lens compartment of the attention, doubtlessly to get rid of the needfor corrective lenses. It is designed to permit the attention’s naturalmuscle exercise to shift focus from distance to close to, offering clearvision in any respect distances with out the assistance of glasses or contact lenses.
FOR FURTHER INFORMATION, PLEASECONTACT:
Dave Burwell
Director, Investor Relations
(403) 410-7907
Neither the TSXVenture Exchange nor its Regulation Services Provider (as that time period isdefined within the insurance policies of the TSX Venture Exchange) acceptsresponsibility for the adequacy or accuracy of this launch.
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKINGINFORMATION: This information launch consists of sure “forward-lookingstatements” beneath relevant Canadian securities laws. Forward-looking statements embrace, however will not be restricted to,statements with respect to the graduation, timing and scope of theresearch and growth to be performed by the Company mentionedabove. Forward-looking statements are essentially based mostly upon anumber of estimates and assumptions that, whereas thought of affordable,are topic to identified and unknown dangers, uncertainties, and otherfactors which can trigger the precise outcomes and future occasions to differmaterially from these expressed or implied by such forward-lookingstatements. Such components embrace however will not be restricted to: operationalmatters, historic tendencies, present situations and anticipated futuredevelopments, entry to financing in addition to different issues thatare believed to be acceptable within the circumstances. There might be noassurance that such statements will show to be correct, as actualresults and future occasions might differ materially from thoseanticipated in such statements. Accordingly, readers mustn’t placeundue reliance on forward-looking statements. The Company disclaimsany intention or obligation to replace or reviseany forward-looking statements, whether or not on account of newinformation, future occasions or in any other case, besides as required bylaw.
Copyright (c) 2026 TheNewswire – All rights reserved.